Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 43,400 shares, an increase of 22.9% from the March 31st total of 35,300 shares. Based on an average daily volume of 65,900 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.3% of the shares of the stock are sold short.
Analyst Upgrades and Downgrades
Separately, LADENBURG THALM/SH SH increased their price target on Aileron Therapeutics from $9.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, April 18th.
View Our Latest Research Report on Aileron Therapeutics
Institutional Investors Weigh In On Aileron Therapeutics
Aileron Therapeutics Price Performance
ALRN stock remained flat at $5.00 during midday trading on Friday. The company’s stock had a trading volume of 85,369 shares, compared to its average volume of 140,703. The company’s fifty day simple moving average is $5.42 and its 200-day simple moving average is $3.74. Aileron Therapeutics has a one year low of $1.01 and a one year high of $7.42.
Aileron Therapeutics (NASDAQ:ALRN – Get Free Report) last posted its earnings results on Monday, April 15th. The company reported ($1.54) earnings per share (EPS) for the quarter. As a group, sell-side analysts anticipate that Aileron Therapeutics will post -0.62 EPS for the current year.
About Aileron Therapeutics
Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.
Further Reading
- Five stocks we like better than Aileron Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 4/22 – 4/26
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Stocks Leading the U.S. Agriculture Comeback
- Using the MarketBeat Dividend Tax Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.